Sep. 12 at 1:05 PM
$KALV "Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on KalVista (KALV) to
$28 from
$27 and keeps an Outperform rating on the shares. Ekterly has seen robust early demand with 460 patient start forms which represents about
$31M in potential revenue, but all patients get 4 doses of free drug and realization of that revenue depends on having and treating attacks and payer access, the analyst tells investors in a research note. The firm adds that consensus estimates near-term will be “unreliable” as KalVista is changing its fiscal year reporting."
https://www.tipranks.com/news/the-fly/kalvista-price-target-raised-to-28-from-27-at-citizens-jmp-thefly
